




PHARMACEUTICAL 2022

InMed Pharmaceuticals Inc.
Rank 321 of 466





PHARMACEUTICAL 2022

InMed Pharmaceuticals Inc.
Rank 321 of 466

The relative strengths and weaknesses of InMed Pharmaceuticals Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of InMed Pharmaceuticals Inc. compared to the market average is the variable Other Liabilities, increasing the Economic Capital Ratio by 25% points. The greatest weakness of InMed Pharmaceuticals Inc. is the variable Net Income, reducing the Economic Capital Ratio by 92% points.

The company's Economic Capital Ratio, given in the ranking table, is 44%, being 34% points below the market average of 78%.

Input Variable	Value in 1000 USD
Assets, Current	8,378
Cost of Goods Sold	0
Intangible Assets	1,062
Liabilities, Current	2,215
Liabilities, Non-Current	189
Other Assets	15
Other Compr. Net Income	430
Other Expenses	121
Other Liabilities	0
Other Net Income	-265
Other Revenues	0
Property and Equipment	327
Research and Development	5,338
Selling, General and Administrative Expense	4,479

Output Variable	Value in 1000 USD
Assets	9,781
Liabilities	2,405
Expenses	9,938
Revenues	0
Stockholders Equity	7,377
Net Income	-10,203
Comprehensive Net Income	-9,988
Economic Capital Ratio	44%